The dividend growth trade is doing something unusual in 2026: it is crushing the broad market. The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has returned roughly 22% year to date on a total-return basis, while the S&P 500 has returned about 8% to 10% over the same stretch. That outperformance gap of more than 12 points in under seven months has refocused attention on a corner of the market that spent much of the last cycle being ignored.
After working through the full dividend growth ETF landscape, three funds keep ending up at the top of the shortlist: SCHD, the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG), and the iShares Core Dividend Growth ETF (NYSEARCA:DGRO). They are not interchangeable. Each runs a different screen, holds a different basket, and serves a different kind of investor. That is precisely the point of owning more than one.
Why Dividend Growth Is Beating the Index Right Now
The leadership in 2026 has rotated away from the megacap growth names that powered 2024 and into companies with real cash flow, durable balance sheets, and conservative payout policies. Dividend growth funds are screening for exactly that profile. They tilt toward healthcare, energy, financials, defense, and staples, sectors that lagged the AI trade and now trade at sensible multiples.
The funds doing the work in this rally are those requiring a track record of raising the dividend, because that screen filters out companies paying out more than they earn. The result is a portfolio that looks boring on paper and has handily beaten the index so far this year.
SCHD: The Standout for Current Income
SCHD tracks the Dow Jones U.S. Dividend 100 Index, which applies a three-factor screen most other dividend ETFs do not use: a 10-year history of consecutive dividend payments, a cash flow to total debt quality check, and a composite ranking on yield and five-year dividend growth. That third leg is what gives SCHD its value tilt and its higher current yield relative to the other two funds on this list.
The portfolio underwent its annual reconstitution in 2026, and the holdings have shifted meaningfully. As of mid-July, top positions include Abbott, UnitedHealth, Merck, Amgen, Home Depot, Procter and Gamble, Coca-Cola, Chevron, PepsiCo, and Verizon, each weighted between roughly 3.7% and 4.5%. Healthcare now represents the largest sector at around 21%, followed closely by consumer defensive names at about 20%. The tight weighting band keeps single-name risk low across this 100-stock book.
The fund carries an expense ratio of 0.06%, one of the cheapest in the dividend category. After recently crossing the $100 billion mark in assets under management, SCHD now stands as the second-largest dividend ETF in the United States. Over the past year the fund has returned about 24%, and total return since inception has compounded at roughly 13% per year.
One development worth monitoring is the distribution trajectory. The Q2 2026 payout came in at $0.253 per share, slightly below the $0.26 paid in Q2 2025, and Q1 2026 also printed below its year-ago comparable. Two consecutive quarters of year-over-year softness in the distribution is a signal that warrants attention, even if the fund’s total return story this year remains strong.
The tradeoff with SCHD is sector concentration. Heavy weights in healthcare and consumer staples mean the fund can lag sharply when the market is paying up for growth and technology. Investors who bought SCHD in 2023 experienced that reality directly. The 2026 rotation is the reverse trade.
VIG: The Quality Compounder
VIG takes a stricter view of what counts as a dividend grower. The fund tracks the S&P U.S. Dividend Growers Index, which requires at least 10 consecutive years of annual dividend increases and explicitly excludes the top 25% highest-yielding eligible names. That exclusion is the whole point. It pushes the portfolio toward companies still in compounding mode rather than payers stretching to defend a high distribution.
The practical result is a megacap-tilted book with a meaningful technology flavor. As of the most recent fact sheet, the top holdings are Broadcom at 4.5%, Apple at 4.2%, Eli Lilly at 4.1%, JPMorgan Chase at 3.6%, and Microsoft at 3.5%, followed by Johnson and Johnson, Lam Research, Visa, and Walmart. That lineup reads more like a quality-growth index than a classic income vehicle, which explains why VIG’s correlation with the S&P 500 is higher than either SCHD or DGRO. The fund carries 334 stocks and a price-to-earnings ratio near 25.
The current yield is the lowest of the three funds here, but the cost of ownership is also the lowest. VIG’s expense ratio is 0.04%, a full two basis points cheaper than SCHD and four cheaper than DGRO. With $110 billion in total net assets, VIG is the largest dividend-focused ETF in the United States. Year to date the fund has returned roughly 8%, and the one-year gain sits near 17%.
VIG paid $0.8334 per share in March, up from $0.5131 for the comparable quarter four years earlier, a steady compounding of the distribution. That rising-payment profile is the whole reason to own the fund. For an investor planning to hold for 20 years, the quality screen and the compounding dynamic are precisely the point.
The tradeoff: if current income is the priority, VIG is the wrong tool. The yield is modest by design. You are buying the rising-payment stream, not the starting check.
DGRO: The Middle Ground
DGRO tracks the Morningstar US Dividend Growth Index, which requires at least five consecutive years of dividend growth and adds a payout ratio screen below 75%. That combination lets the fund include some higher-yielders VIG screens out, while still demanding the earnings quality that a payout-ratio cap enforces. The result is a fund that lands between SCHD and VIG on almost every dimension that matters.
The expense ratio of 0.08% keeps DGRO competitive with the cheapest funds in the category, though it is the most expensive of this trio. The fund manages roughly $41 billion in assets and carries a 12-month trailing yield near 2%. Its inception in June 2014 gives it more than a decade of live track record, during which it has compounded at roughly 13% per year, essentially matching VIG’s long-term result. Year to date DGRO has returned about 10%, with a 21% one-year gain, splitting the difference between SCHD’s value-led surge and VIG’s quality-growth profile.
The dividend cadence has been steady, with the December 2025 payment of $0.4470 per share running well ahead of the prior December’s $0.3780, a sign the underlying holdings are pushing distributions higher. The tradeoff with DGRO is its middle-ground positioning. It rarely tops a leaderboard. In a year like 2026 where SCHD’s screen is in favor, DGRO trails SCHD. In a year where megacap growers run, it trails VIG.
Which Fund Fits Which Investor
If current income is the priority, SCHD is the clearest choice on this list. The higher yield, the value tilt, and the three-factor quality screen do exactly what a retiree or near-retiree wants from an equity sleeve: pay cash now, hold up in drawdowns, and avoid the speculative end of the dividend market. The $100 billion milestone also signals deep liquidity and institutional acceptance.
For someone 20 or 30 years from drawing down the portfolio, VIG is the better long-term compounder. The 10-year increase requirement and the high-yield exclusion both push the fund toward businesses that reinvest, grow, and gradually raise the payment. Those are the holdings suited to owning your capital for two decades, and the 0.04% expense ratio means more of the return stays with the investor.
DGRO is the fund for the investor who does not want to choose. It captures most of the dividend growth premium with some current income on top, at a cost close to the cheapest funds in the category. For a single-ETF dividend allocation inside a balanced portfolio, that profile is hard to beat. The three funds are complementary, and the reason all three keep showing up on serious shortlists is that each one is the right answer to a different question.
Editor’s note: This article has been updated to reflect SCHD’s crossing of $100 billion in assets under management, its post-reconstitution top holdings (now led by Abbott, UnitedHealth, Merck, Amgen, and Home Depot), and two consecutive quarters of year-over-year distribution softness in Q1 and Q2 2026. Performance figures for all three funds have been refreshed to mid-July 2026 data, including SCHD’s roughly 22% total return year to date, VIG’s approximately 8% gain, and DGRO’s approximately 10% gain. VIG’s 0.04% expense ratio and $110 billion in total net assets have also been added.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks